Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Stopped early · Phase 2

Conditions studied: Myelodysplastic Syndrome

In brief

This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles of lenalidomide. Patients who respond may given additional cycles of lenalidomide until disease progression.

Key facts

Study ID

NCT00867308

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

32

Starts

2009-07-01

Expected to finish

2014-05-01

Last updated by the study team

2018-10-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than 18 years at the time of signing the informed consent form.
• Able to adhere to the study visit schedule and other protocol requirements.
• MDS or MDS/AML
• Patients must not have received any other treatment for their disease, including hematopoietic growth factors, within three weeks of beginning the trial
• ECOG performance status of 0, 1, or 2 at study entry
• All study participants must be registered into the mandatory REMS® program, and be willing and able to comply with the requirements of RevAssist®.
• Patients must have no clinical evidence of CNS or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia.
• Subjects must agree to use appropriate contraception.

You may not qualify if…

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Use of any other experimental drug or therapy within 21 days of baseline.
• Known hypersensitivity to thalidomide.
• The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
• Any prior use of lenalidomide except for MDS patients with del 5q31.1 abnormalities..
• Concurrent use of other anti-cancer agents or treatments.
• Patients may not have received prior AML induction chemotherapy or stem cell transplant. However, patients with secondary MDS who have received a stem cell transplant for other indications (eg lymphoma, multiple myeloma) will be eligible.

Where it is running

• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.